<DOC>
	<DOCNO>NCT01927588</DOCNO>
	<brief_summary>CMV infection common transplant patient cause graft loss . CMV major factor increase morbidity , post-transplant cost . The CMV infection associate many deleterious indirect effect include rejection , interstitial fibrosis tubular atrophy , mortality . In addition potential undesirable clinical outcome associate CMV , also negative economic aspect . Patients develop CMV event find use significantly inpatient outpatient resource patient without CMV disease . Universal prophylaxis associate high treatment cost potential drug-related toxicity . It speculate use EVR may offer additional economic benefit term decrease utilization associate prevention CMV disease , reduce use costly prophylaxis . Any effort reduce cost renal transplant important may great impact total cost renal program . And hand , clinical data suggest EVR associate decrease CMV incidence compare mycophenolic acid ( MPA ) . CMV replication dependent upon 1 ou 2 mTor pathway vitro study support association mTor inhibitor decrease CMV infection disease . In cardiac transplantation , use EVR associate low incidence CMV event . Some clinical trial data also show use EVR associate low incidence CMV infection compare MPA follow renal transplantation . Brennan et al compare incidence CMV three clinical trial use EVR versus MPA De Novo renal transplant . They pool analysis study B201 , B251 A2309 , double-blind , randomize , parallel-groups compare incidence freedom form incidence CMV EVR group MPA group . The result pool analysis 2000 patient de novo renal transplant demonstrate EVR associate decrease delay time onset CMV event compare MPA . Our hypothesis basiliximab combination low dose tacrolimus , everolimus prednisone may result comparable efficacy ( BCAR ) observe patient receive tacrolimus/mycophenolate/prednisone good safety profile ( CMV infection ) cost-effectiveness .</brief_summary>
	<brief_title>Evaluation Early Use Everolimus ( EVE ) Cytomegalovirus ( CMV ) Infection Renal Transplant Recipients</brief_title>
	<detailed_description>Objectives : Primary To investigate effect early use EVL plus TAC dose reduce vs. MPS plus TAC full dose CMV infection antigenemia 12 month transplantation stable kidney transplant recipient . Secondaries To evaluate renal function cGFR ( MDRD ) To evaluate incidence acute rejection nephrotoxicity protocol biopsy ; To evaluate incidence poliomavirus , accord treatment group , quantitative PCR BKviremia urine biopsy sample .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Primary kidney transplant ( live decease donor ) ; Recipients second transplant ; Recipients multiple organ transplant ; PRA &gt; 50 % ; Chronic liver failure ; Presence uncontrolled hypercholesterolemia ( ≥ 250 mg/dL ) ; Or hypertriglyceridemia ( ≥ 300 mg/dL ) . Leucocytes count &lt; 1500 per microliter ; Platelets count &lt; 75000 per microliter ; Proteinuria &gt; 800mg/day ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Certican</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Cytomegalovirus Infection</keyword>
</DOC>